Search

Your search keyword '"Packard, Chris J"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Packard, Chris J" Remove constraint Author: "Packard, Chris J" Database OAIster Remove constraint Database: OAIster
62 results on '"Packard, Chris J"'

Search Results

1. Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism

2. Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism

3. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

4. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

5. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

6. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.

7. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

8. Triglyceride-rich lipoproteins and their remnants:Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society

9. Triglyceride-rich lipoproteins and their remnants : metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

10. Triglyceride-rich lipoproteins and their remnants:Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society

11. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

12. Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals.

13. Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals

14. Low-density lipoproteins cause atherosclerotic cardiovascular disease:Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel

15. Low-density lipoproteins cause atherosclerotic cardiovascular disease:Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel

16. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

17. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm:conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

18. Publisher Correction : Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.

19. Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

20. Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

21. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

22. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

23. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

24. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

25. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

26. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

27. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

28. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

29. Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic, epidemiologic, and clinical studies:. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

30. Rare and low-frequency coding variants alter human adult height

31. Rare and low-frequency coding variants alter human adult height

32. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

33. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

34. Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic, epidemiologic, and clinical studies:. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

35. Genetic invalidation of Lp-PLA2 as a therapeutic target:Large-scale study of five functional Lp-PLA2-lowering alleles

36. Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic, epidemiologic, and clinical studies:. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

37. Genetic invalidation of Lp-PLA2 as a therapeutic target:Large-scale study of five functional Lp-PLA2-lowering alleles

38. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

39. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

40. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

41. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

42. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.

43. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.

44. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

45. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

46. Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels

47. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

48. Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels

49. Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels

50. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

Catalog

Books, media, physical & digital resources